ENGNW
enGene Holdings Inc. WarrantsNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
—
Beta
-0.28
52W High
$4.20
52W Low
$0.12
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About enGene Holdings Inc. Warrants
enGene Holdings Inc., through its subsidiary enGene, Inc., is a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. The company is headquartered in Saint-Laurent, Canada.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-131.91M |
| Operating Margin | 0.00% |
| Return on Equity | -52.60% |
| Return on Assets | -28.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.81 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $19.13M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
—
HV 20-Day
—
HV 30-Day
—
HV 60-Day
—
HV Rank
—
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ENGNW and any ticker you trade — then tracks every position and per-strategy win rate.
Data last updated: 7/29/2026